newsfilter
← Latest News
Business Wire·

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024